Scholar Rock (SRRK) Projected to Post Quarterly Earnings on Friday

Scholar Rock (NASDAQ:SRRK) is anticipated to release its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect Scholar Rock to post earnings of ($0.88) per share and revenue of $0.05 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 14, 2025 at 8:00 AM ET.

Scholar Rock Stock Up 4.8%

SRRK opened at $30.79 on Wednesday. The business’s fifty day simple moving average is $32.45 and its 200 day simple moving average is $33.39. Scholar Rock has a 52 week low of $22.71 and a 52 week high of $46.98. The company has a quick ratio of 6.33, a current ratio of 6.33 and a debt-to-equity ratio of 0.21. The stock has a market cap of $2.96 billion, a PE ratio of -10.58 and a beta of 0.79.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SRRK. Piper Sandler decreased their price objective on Scholar Rock from $52.00 to $51.00 and set an “overweight” rating on the stock in a report on Wednesday, September 24th. Cantor Fitzgerald assumed coverage on shares of Scholar Rock in a report on Thursday, July 17th. They issued an “overweight” rating for the company. Raymond James Financial set a $53.00 price objective on shares of Scholar Rock and gave the company a “strong-buy” rating in a research note on Wednesday, July 30th. BMO Capital Markets lowered their price objective on Scholar Rock from $57.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. Finally, Leerink Partners initiated coverage on shares of Scholar Rock in a report on Monday, September 15th. They issued an “outperform” rating and a $51.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $48.50.

Insider Buying and Selling

In related news, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $32.53, for a total value of $32,725.18. Following the sale, the director owned 33,914 shares in the company, valued at $1,103,222.42. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Srinivas Akkaraju acquired 113,025 shares of the firm’s stock in a transaction on Monday, October 6th. The stock was bought at an average price of $38.65 per share, with a total value of $4,368,416.25. Following the completion of the acquisition, the director directly owned 500,439 shares in the company, valued at approximately $19,341,967.35. This represents a 29.17% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 7,537 shares of company stock valued at $242,088 over the last quarter. 13.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Scholar Rock

Several hedge funds have recently bought and sold shares of SRRK. California State Teachers Retirement System boosted its stake in Scholar Rock by 0.9% during the 2nd quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock valued at $2,209,000 after purchasing an additional 577 shares during the last quarter. E Fund Management Co. Ltd. lifted its holdings in shares of Scholar Rock by 6.8% during the second quarter. E Fund Management Co. Ltd. now owns 11,146 shares of the company’s stock valued at $395,000 after purchasing an additional 710 shares in the last quarter. Strs Ohio purchased a new stake in shares of Scholar Rock during the first quarter valued at $77,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Scholar Rock by 12.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after buying an additional 5,831 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Scholar Rock by 288.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,115 shares of the company’s stock worth $323,000 after buying an additional 6,768 shares during the last quarter. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.